Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02568878 · ClinicalTrials.gov registry record · Phase 3

Creatine for Depressed Male and Female Methamphetamine Users

A Phase 3 study of Depression and Anxiety, sponsored by Montana State University.

Recruiting
Registry status
Phase 3
Development phase
29
Enrollment target
1
Study location

NCT02568878: Recruiting Phase 3 study of Depression and Anxiety, sponsored by Montana State University.

NCT02568878 is a Phase 3 study of Depression and Anxiety that is actively recruiting participants, run by Montana State University. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02568878, a Phase 3 study of Depression and Anxiety, is actively recruiting participants, sponsored by Montana State University.

RECRUITING
Registry status
Phase 3
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

Interventions

  • DRUG Creatine monohydrate

Study Locations (1)

Montana

  • Montana State University College of Nursing (Missoula campus) - Missoula

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2015-11
Est. Completion 2017-05
Phase Phase 3
Montana State University

36 total trials

What NCT02568878 shows while recruiting

NCT02568878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Creatine monohydrate is the first listed.

NCT02568878 reports a single indexed study location in Montana.

Frequently Asked Questions

What is clinical trial NCT02568878 about?

NCT02568878 is a clinical study titled "Creatine for Depressed Male and Female Methamphetamine Users". * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

What is the current status of trial NCT02568878?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2015-11. Estimated completion is 2017-05.

What conditions does trial NCT02568878 study?

This clinical trial studies the following conditions: Depression, Anxiety, Methamphetamine-dependence.

What interventions are being tested in trial NCT02568878?

The interventions under investigation include: Creatine monohydrate (DRUG).

Who is sponsoring clinical trial NCT02568878?

This trial is sponsored by Montana State University, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02568878 being conducted?

This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02568878's enrollment target sits among peer trials

29 576th of 679 higher than 99 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

  • NCT03531450 · 29 participants · NA

    Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02568878, the US trial registry maintained by the National Library of Medicine. NCT02568878 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.